Non-Coding RNA Assays Market Analysis

  • Report ID: 3730
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Non-Coding RNA Assays Market Analysis

End-user (Laboratories, Research Centers, Hospitals, Ambulatory Surgical Centers)

The global non-coding RNA assays market is segmented and analyzed for demand and supply by end-user into laboratories, research centers, hospitals, ambulatory surgical centers, and others. Out of the five end-users, the research centers segment is estimated to gain the largest market share in the year 2036. The growth of the segment can be attributed to the increasing prevalence of chronic diseases across the globe. For instance, since ncRNA tests have the potential to serve as biomarkers for illness diagnosis and prognosis, their application in research institutions is becoming more and more crucial. In addition, for a number of illnesses, including cancer, cardiovascular disease, and neurological disorders, ncRNA expression patterns can be employed as biomarkers. Today, an approximate 133 million Americans, or nearly fifty percent of the population, have at least one chronic disease, including hypertension, cardiovascular disease, or arthritis. This figure is 15 substantially larger than a decade ago, and it is projected to surpass 170 million by 2030.

The global non-coding RNA assays market is also segmented and analyzed for demand and supply by end-user into laboratories, research centers, hospitals, ambulatory surgical centers, and others. Amongst these five segments, the laboratories segment is expected to garner a significant share in the year 2036. Using ncRNA assays in laboratory settings is a fast-developing discipline as it offers a potent tool for comprehending how gene expression is regulated and assists in locating possible treatment targets. Besides this, the expression of diverse ncRNA types, including microRNAs, long non-coding RNAs, and small interfering RNAs, in various tissues and cell types may be examined using ncRNA assays in laboratories. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global market includes the following segments:

    By Type

  • Regulatory
  • Investigative

     By Size

  • Small (Less than 360 Reactions)
  • Medium (360-750 Reactions)
  • Large (2900 Reactions)
  • Others

    By End User

  • Laboratories
  • Research Centers
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3730
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of non-coding rna assays is estimated at USD 304.19 Million.

The non-coding rna assays market size was valued at USD 269.08 Million in 2023 and is projected to cross USD 1.56 Billion by the end of 2036, expanding at more than 14.5% CAGR during the forecast period i.e., between 2024-2036. Growing prevalence of chronic diseases, and rising geriatric population are the major factors driving the market growth.

North America is anticipated to grow with the highest CAGR through 2036, attributed to availability of a large number of biotechnology and pharmaceutical companies.

Thermo Fisher Scientific Company, Springer Nature Limited, Applied Microarrays Inc., C D Genomics, RELX Group, MilliporeSigma, QIAGEN, Agilent Technologies, Inc., Danaher Corporation, Eppendorf SE
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample